



FKHR (Ab-256) Antibody

#21138

Catalog Number: 21138-1, 21138-2

Amount: 50 μ g/50 μ l, 100 μ g/100 μ l

Swiss-Prot No. : Q12778

Form of Antibody: Rabbit IgG in phosphate buffered saline (without Mg^{2+} and Ca^{2+}), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability: Store at $-20^{\circ}C$ /1 year

Immunogen: The antiserum was produced against synthesized non-phosphopeptide derived from human FKHR around the phosphorylation site of serine 256 (A-A-S_P-M-D).

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen


Specificity/Sensitivity: FKHR (Ab-256) antibody detects endogenous levels of total FKHR protein

Reactivity: Human, Mouse, Rat



Applications:

Predicted MW: 78-82kd

WB: 1:500~1:1000 IHC: 1:50~1:100 IF:1:100~1:200



Peptide - +
Immunohistochemical analysis of paraffin-embedded
human breast carcinoma tissue using FKHR (Ab-256)antibody (#21138).



Immunofluorescence staining of methanol-fixed HeLa cells using FKHR (Ab-256) antibody (#21138, Red).

Background :

FKHR belongs to the forkhead family of transcription factors, which are characterized by a distinct forkhead domain. It may play a role in myogenic growth and differentiation. The mammalian DAF-16-like transcription factors, FKHR, FKHL1, and AFX, function as key regulators of insulin signaling, cell cycle progression, and apoptosis downstream of phosphoinositide 3-kinase. Gene activation through binding to insulin response sequences has been essential for mediating these functions. D-type Cyclins (in Class III) is required for FKHR mediated inhibition of cell cycle progression and transformation. FKHR gene is mapped to chromosome 13q14

References:

- Gan L, et al. (2005) J Neurochem; 93(5): 1209-19.
Smith WW, et al. (2005) J Cell Biol; 169(2): 331-9.
Di Maira G, et al. (2005) Cell Death Differ; 12(6): 668-77.
Horn S, et al. (2004) Leukemia; 18(11): 1839-49.
Zhao X, et al. (2004) Biochem J 4; 378(Pt 3): 839-49.